A Randomized, Prospective, Double-Blind Clinical Trial on the Optimal Dose of Oral Midazolam Premedication in Pediatric Day Case Surgery
Objectives: Anxiolysis and sedation with oral midazolam are common practice in pediatric anesthesia. The aim of the present study was to evaluate the efficacy and safety of 3 different doses of midazolam as a premedication agent in day case pediatric surgery patients.
Methods: This prospective, randomized, double-blind clinical investigation was designed at Medeniyet University Göztepe Education and Training Hospital Department of Anesthesiology and Reanimation. In all, 90 children aged 6 months to 6 years with American Society of Anesthesiologists physical status of class I or II, who were scheduled for inguinal hernia repair or hydrocele operation were included in the study. Patients were randomly allocated into 3 groups to receive midazolam premedication 0.3 mg kg-1 (Group I), 0.5 mg kg-1 (Group II), or 0.75 mg kg-1 (Group III). Psychological, behavioral, and physiological parameters (heart rate, mean arterial pressure, arterial oxygen saturation, respiratory rate, sedation, anxiolysis score and mask toleration score) were recorded at particular time intervals and special stressful events (separation from parents, induction of anesthesia). Adverse events were also noted.
Results: Satisfactory sedation was achieved in all groups. At the end of the operation, the sedation score was higher in Group III. The anxiety rating of face mask application was satisfactory in Group II. There were significant differences between groups in hemodynamic variables, oxygen saturation, and respiratory rate. However, they were accepted as clinically insignificant. There was no significant difference in separation scores between the 3 groups. Postoperative vomiting occurred in 3 patients in Group II and in 2 patients in Group III. Also in Group III, recovery was late in 2 patients and agitation was seen in 2 patients.
Conclusion: A dose of 0.3-0.75 mg kg-1 oral midazolam can be used safely for the premedication of pediatric patients to provide sufficient sedation, a pleasant separation from the parents, and fair tolerance of face mask application.
1.Kain ZN, Mayes LC, Bell C, Weisman S, Hofstadter MB, Rimar S. Premedication in the United States: a status report. Anesth Analg 1997;84:427–32.
2. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juicedrug interactions. Br J Clin Pharmacol 1998;46:101–10.
3. Naqash I, Nisa W, Zargar J, Farooqi A. Midazolam premedication in children: comparison of nasal and sublingual routes. J Anaesth Clin Pharmacol 2004;20:141–5.
4. Hannallah RS, Epstein BS. The paediatric patient. In: Wetchler VV, editor. Anesthesia for ambulatory surgery. 2nd ed. Philadelphia: JB Lippincott; 1997. p. 131–95.
5. Karl HW, Keifer AT, Rosenberger JL, Larach MG, Ruffle JM. Comparison of the safety and efficacy of intranasal midazolam or sufentanil for preinduction of anesthesia in pediatric patients. Anesthesiology 1992;76:209–15. [CrossRef]
6. Geldner G, Hubmann M, Knoll R, Jacobi K. Comparison between three transmucosal routes of administration of midazolam in children. Paediatr Anaesth 1997;7:103–9. [CrossRef]
7. McMillan CO, Spahr-Schopfer IA, Sikich N, Hartley E, Lerman J. Premedication of children with oral midazolam. Can J Anaesth 1992;39:545–50. [CrossRef]
8. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491–502. [CrossRef]
9. Wandel C, Böcker R, Böhrer H, Browne A, Rügheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994;73:658–61. [CrossRef]
10. Hiller A, Olkkola KT, Isohanni P, Saarnivaara L. Unconsciousness associated with midazolam and erythromycin. Br J Anaesth 1990;65:826–8. [CrossRef]
11. Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999;39:1109–25.
12. Pelkonen O, Mäenpää J, Taavitsainen P, Rautio A, Raunio H. Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica 1998;28:1203–53. [CrossRef]
13. Watanabe M, Tateishi T, Asoh M, Nakura H, Tanaka M, Kumai T, et al. Effects of glucocorticoids on pharmacokinetics and pharmacodynamics of midazolam in rats. Life Sci 1998;63:1685–92.
14. Mishra LD, Sinha GK, Bhaskar Rao P, Sharma V, Satya K, Gairola R. Injectable midazolam as oral premedicant in pediatric neurosurgery. J Neurosurg Anesthesiol 2005;17:193–8. [CrossRef]
15. Coté CJ, Cohen IT, Suresh S, Rabb M, Rose JB, Weldon BC, et al. A comparison of three doses of a commercially prepared oral midazolam syrup in children. Anesth Analg 2002;94:37–43.
16. Ko YP, Huang CJ, Hung YC, Su NY, Tsai PS, Chen CC, et al. Premedication with low-dose oral midazolam reduces the incidence and severity of emergence agitation in pediatric patients following sevoflurane anesthesia. Acta Anaesthesiol Sin 2001;39:169–77.
17. Brosius KK, Bannister CF. Midazolam premedication in children: a comparison of two oral dosage formulations on sedation score and plasma midazolam levels. Anesth Analg 2003;96:392–5. [CrossRef]
18. Levine MF, Spahr-Schopfer IA, Hartley E, Lerman J, MacPherson B. Oral midazolam premedication in children: the minimum time interval for separation from parents. Can J Anaesth 1993;40:726–9. [CrossRef]
19. Parnis SJ, Foate JA, van der Walt JH, Short T, Crowe CE. Oral midazolam is an effective premedication for children having day-stay anaesthesia. Anaesth Intensive Care 1992;20:9–14.
20. Feld LH, Negus JB, White PF. Oral midazolam preanesthetic medication in pediatric outpatients. Anesthesiology 1990;73:831–4. [CrossRef]
21. Arai YC, Ito H, Kandatsu N, Kurokawa S, Kinugasa S, Komatsu T. Parental presence during induction enhances the effect of oral midazolam on emergence behavior of children undergoing general anesthesia. Acta Anaesthesiol Scand 2007;51:858–61.
22. Kazak Z, Sezer GB, Yilmaz AA, Ates Y. Premedication with oral midazolam with or without parental presence. Eur J Anaesthesiol 2010;27:347–52. [CrossRef]